A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.
- 19 Sep 2017 Planned End Date changed from 1 Aug 2021 to 1 Oct 2021.